Cell Therapy News/Articles, page-16824

Mums, Dad's & Newbies I'm certain you do your appropriate diligence and engage professionals who possess the required Financial Services Licence "FSL" in lieu of being passively influenced through a negative narritive particularly from forum participants that are non holders of a Company stock holding. This constant barrage is a red flag for myself as personally I'm acutely aware of the challenges a biotech company has in their attempts to gain regulatory approval and sufficient funding to support a new treatment for people's wellbeing. The proof of greed is arguably visible with more than 7% or 60 million short positions that remain open. What comes to mind is Surgcentre investment at around $2.30 and Mr Gregory George who has purchased more stock which appears to support Chronic Heart Failure treatment which has been a significant burden on people for far too long and the frightening thing here is CHF does not discriminate. I'm hopeful of the FDA acknowledging and accepting an accelerated approval for CHF as well as collaboration towards CLBP that i s well and truly overdue. This is my view of a speculative small Biotech Company overseen by a CEO that posses an industry credibility in stem cell, quite frankly his expertise is unquestionably seen as the industry leader and he will dedicate his life passion to realise FDA approval.